DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Recruiting · NCT07288112 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT07288112 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Diakonos Oncology Corporation | 3 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Arizona State University-Honor Health Research Institute | Scottsdale | United States | 1 |
| Atlantic Health | Morristown | United States | 10 |
| Banner Md Anderson Cancer Center | Gilbert | United States | 121 |
| City of Hope | Duarte | United States | 238 |
| Massachusetts General Hospital Cancer Institute | Boston | United States | 1 |
| The University of Alabama at Birmingham | Birmingham | United States | 17 |
| University of North Carolina | Chapel Hill | United States | 101 |
| UT Southwestern | Dallas | United States | 11 |